Connecta Therapeutics
Connecta Therapeutics develops small-molecule treatments for neurological disorders, including CTH120, a clinical-stage candidate for Fragile X syndrome.
€3.1MClinical development financing
LeadCC
Clave Capital
Activity from announced rounds
All recorded activity
- Rounds participated in
- 2
- Confirmed lead rounds
- 1 1 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $10.7M 2 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
2 in all activityPharmacelera
Pharmacelera uses quantum-mechanics methods and AI in drug discovery.
€6MGrowth
Role not disclosed